Clara Furió-Novejarque
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Clara Furió-Novejarque has a total of 33 co-authors. Here are the top co-authors by number of shared publications:
- Jorge Bondia
Instituto Universitario de Automática e Informática Industrial Universitat Politècnica de València Valencia Spain
7 shared publications - José-Luis Díez
Instituto Universitario de Automática e Informática Industrial Universitat Politècnica de València Valencia Spain
6 shared publications - Iván Sala-Mira
Instituto Universitario de Automática e Informática Industrial, Universitat Politècnica de València, València, Spain; Centro de Investigación Biomédica en Red de Diabetes y Enfermedades Metabólicas Asociadas, Instituto de Salud Carlos III, Madrid, Spain
4 shared publications Jorge Bondia
2 shared publicationsJosé-Luis Díez
Instituto Universitario de Automática e Informática Industrial, Universitat Politècnica de València, Valencia, Spain
2 shared publications- Pedro García
Universitat Politècnica de València
2 shared publications
Latest Publications
- Open Access
- 24 October 2026
- Published by Elsevier in Control Engineering Practice
- Vol. 178
Control-oriented modeling of glucose insulin dynamics with dynamic insulin sensitivity
- 24 October 2026
- Published by Elsevier in Control Engineering Practice
- Vol. 178
Open AccessControl-oriented modeling of glucose insulin dynamics with dynamic insulin sensitivity
- Open Access
- 15 September 2026
- Published by Wiley in Bioengineering & Translational Medicine
- Vol. 11 (6) , e70168
Modeling ovarian hormone effects on glucose–insulin control in type 1 diabetes
Women with type 1 diabetes mellitus (T1DM) may experience challenges in glycemic control driven by biological sex–specific hormonal fluctuations. Across the menstrual cycle, clinical studies have reported phase‐dependent variations in time in range (TIR), with periods of increased hyperglycemia associated with changes in insulin sensitivity (IS). However, IS is not the sole metabolic process influenced by ovarian hormones; multiple regulatory mechanisms involved in glucose homeostasis appear to be modulated, adding complexity to insulin therapy management in women with T1DM using current automated insulin delivery (AID) systems. In this context, the present work conducts a narrative review of physiologically based mathematical models that seek to couple ovarian hormonal dynamics with glucose–insulin regulation. The analysis reveals a limited number of models that explicitly integrate these interacting systems, highlighting important gaps in the current modeling landscape. These findings underscore the need for physiologically informed models that more accurately represent hormonal–metabolic interactions in women with T1DM, with potential implications for the future development of sex‐specific simulation tools and adaptive closed‐loop insulin delivery strategies.
- 15 September 2026
- Published by Wiley in Bioengineering & Translational Medicine
- Vol. 11 (6) , e70168
Open AccessModeling ovarian hormone effects on glucose–insulin control in type 1 diabetes
Women with type 1 diabetes mellitus (T1DM) may experience challenges in glycemic control driven by biological sex–specific hormonal fluctuations. Across the menstrual cycle, clinical studies have reported phase‐dependent variations in time in range (TIR), with periods of increased hyperglycemia associated with changes in insulin sensitivity (IS). However, IS is not the sole metabolic process influenced by ovarian hormones; multiple regulatory mechanisms involved in glucose homeostasis appear to be modulated, adding complexity to insulin therapy management in women with T1DM using current automated insulin delivery (AID) systems. In this context, the present work conducts a narrative review of physiologically based mathematical models that seek to couple ovarian hormonal dynamics with glucose–insulin regulation. The analysis reveals a limited number of models that explicitly integrate these interacting systems, highlighting important gaps in the current modeling landscape. These findings underscore the need for physiologically informed models that more accurately represent hormonal–metabolic interactions in women with T1DM, with potential implications for the future development of sex‐specific simulation tools and adaptive closed‐loop insulin delivery strategies.
- Open Access
- 12 June 2025
- Published by Elsevier in Computers in Biology and Medicine
- Vol. 194, 110447
In silico evaluation of pramlintide dosing algorithms in artificial pancreas systems
- 12 June 2025
- Published by Elsevier in Computers in Biology and Medicine
- Vol. 194, 110447
Open AccessIn silico evaluation of pramlintide dosing algorithms in artificial pancreas systems
- 16 October 2024
- Published by SAGE Publications in Journal of Diabetes Science and Technology
GLP-1 Receptor Agonists Models for Type 1 Diabetes: A Narrative Review
Background: Glucagon-like peptide 1 (GLP-1) is a hormone that promotes insulin secretion, delays gastric emptying, and inhibits glucagon secretion. The GLP-1 receptor agonists have been developed as adjunctive therapies for type 2 diabetes to improve glucose control. Recently, there has been an interest in introducing GLP-1 receptor agonists as adjunctive therapies in type 1 diabetes alongside automatic insulin delivery systems. The preclinical validation of these systems often relies on mathematical simulators that replicate the glucose dynamics of a person with diabetes. This review aims to explore mathematical models available in the literature to describe GLP-1 effects to be used in a type 1 diabetes simulator. Methods: Three databases were examined in the search for GLP-1 mathematical models. More than 1500 works were found after searching for specific keywords that were narrowed down to 39 works for full-text assessment. Results: A total of 23 works were selected describing GLP-1 pharmacokinetics and pharmacodynamics. However, none of the found models was designed for type 1 diabetes. An analysis is included of the available models’ features that could be translated into a GLP-1 receptor agonist model for type 1 diabetes. Conclusion: There is a gap in research in GLP-1 receptor agonists mathematical models for type 1 diabetes, which could be incorporated into type 1 diabetes simulators, providing a safe and inexpensive tool to carry out preclinical validations using these therapies.
- 16 October 2024
- Published by SAGE Publications in Journal of Diabetes Science and Technology
GLP-1 Receptor Agonists Models for Type 1 Diabetes: A Narrative Review
Background: Glucagon-like peptide 1 (GLP-1) is a hormone that promotes insulin secretion, delays gastric emptying, and inhibits glucagon secretion. The GLP-1 receptor agonists have been developed as adjunctive therapies for type 2 diabetes to improve glucose control. Recently, there has been an interest in introducing GLP-1 receptor agonists as adjunctive therapies in type 1 diabetes alongside automatic insulin delivery systems. The preclinical validation of these systems often relies on mathematical simulators that replicate the glucose dynamics of a person with diabetes. This review aims to explore mathematical models available in the literature to describe GLP-1 effects to be used in a type 1 diabetes simulator. Methods: Three databases were examined in the search for GLP-1 mathematical models. More than 1500 works were found after searching for specific keywords that were narrowed down to 39 works for full-text assessment. Results: A total of 23 works were selected describing GLP-1 pharmacokinetics and pharmacodynamics. However, none of the found models was designed for type 1 diabetes. An analysis is included of the available models’ features that could be translated into a GLP-1 receptor agonist model for type 1 diabetes. Conclusion: There is a gap in research in GLP-1 receptor agonists mathematical models for type 1 diabetes, which could be incorporated into type 1 diabetes simulators, providing a safe and inexpensive tool to carry out preclinical validations using these therapies.
- Open Access
- 24 August 2024
- Published by Elsevier in Biocybernetics and Biomedical Engineering
- Vol. 44 (3) , 560-568
In silico validation of a customizable fully-autonomous artificial pancreas with coordinated insulin, glucagon and rescue carbohydrates
- 24 August 2024
- Published by Elsevier in Biocybernetics and Biomedical Engineering
- Vol. 44 (3) , 560-568
Open AccessIn silico validation of a customizable fully-autonomous artificial pancreas with coordinated insulin, glucagon and rescue carbohydrates
- Open Access
- 24 June 2024
- Published by Elsevier in IFAC Journal of Systems and Control
- Vol. 29
Analysis on the contribution of glucagon receptors to glucose dynamics in type 1 diabetes
- 24 June 2024
- Published by Elsevier in IFAC Journal of Systems and Control
- Vol. 29
Open AccessAnalysis on the contribution of glucagon receptors to glucose dynamics in type 1 diabetes
- 5 December 2023
- Published by Elsevier in Computer Methods and Programs in Biomedicine
- Vol. 244, 107968
A model of subcutaneous pramlintide pharmacokinetics and its effect on gastric emptying: Proof-of-concept based on populational data
- 5 December 2023
- Published by Elsevier in Computer Methods and Programs in Biomedicine
- Vol. 244, 107968
A model of subcutaneous pramlintide pharmacokinetics and its effect on gastric emptying: Proof-of-concept based on populational data
- 24 January 2023
- Published by Elsevier in Computers in Biology and Medicine
- Vol. 154, 106605
Modeling the effect of glucagon on endogenous glucose production in type 1 diabetes: On the role of glucagon receptor dynamics
- 24 January 2023
- Published by Elsevier in Computers in Biology and Medicine
- Vol. 154, 106605
Modeling the effect of glucagon on endogenous glucose production in type 1 diabetes: On the role of glucagon receptor dynamics
- 27 August 2020
- Published by The Endocrine Society in The Journal of Clinical Endocrinology & Metabolism
- Vol. 106 (1) , 55-63
Artificial Pancreas With Carbohydrate Suggestion Performance for Unannounced and Announced Exercise in Type 1 Diabetes
OBJECTIVE To evaluate the safety and performance of a new multivariable closed-loop glucose controller with automatic carbohydrate recommendation (MCL) during and after unannounced and announced exercise in adults with type 1 diabetes (T1D). RESEARCH DESIGN AND METHODS A randomized, three-arm, crossover clinical trial was conducted. Participants completed a heavy aerobic exercise session including three 15-min sets on a cycle-ergometer with 5 minutes rest in-between. In a randomly determined order, we compared MCL control with unannounced (CLNA) and announced (CLA) exercise to open-loop therapy (OL). Adults with T1D, insulin pump users and HbA1c between 6.0-8.5% were eligible. We investigated glucose control during and 3 hours after exercise. RESULTS Ten subjects (40.8±7.0 years-old; an HbA1c of 7.3±0.8%) participated. The use of the MCL in both closed-loop arms decreased the time <70 mg/dl of sensor glucose (0.0%,[0.0-16.8] and 0.0%,[0.0-19.2] vs. 16.2%,[0.0-26.0], (%,[Percentile 10-90]) CLNA and CLA vs. OL respectively, p=0.047,p=0.063) and the number of hypoglycemic events when compared to OL (CLNA 4 and CLA 3 vs. OL 8; p=0.218,p=0.250). The use of MCL system increased the proportion of time within 70-180 mg/dl (87.8%,[51.1-100] and 91.9%,[58.7-100] vs. 81.1%,[65.4-87.0], (%,[Percentile 10-90]) CLNA and CLA vs. OL respectively, p=0.227, p=0.039). This was achieved with the administration of similar doses of insulin and less amount of carbohydrates. CONCLUSIONS MCL with automatic carbohydrate recommendation performed well and was safe during and after both unannounced and announced exercise maintaining glucose mostly within the target range and reducing the risk of hypoglycemia despite of less amount of carbohydrate intake.
- 27 August 2020
- Published by The Endocrine Society in The Journal of Clinical Endocrinology & Metabolism
- Vol. 106 (1) , 55-63
Artificial Pancreas With Carbohydrate Suggestion Performance for Unannounced and Announced Exercise in Type 1 Diabetes
OBJECTIVE To evaluate the safety and performance of a new multivariable closed-loop glucose controller with automatic carbohydrate recommendation (MCL) during and after unannounced and announced exercise in adults with type 1 diabetes (T1D). RESEARCH DESIGN AND METHODS A randomized, three-arm, crossover clinical trial was conducted. Participants completed a heavy aerobic exercise session including three 15-min sets on a cycle-ergometer with 5 minutes rest in-between. In a randomly determined order, we compared MCL control with unannounced (CLNA) and announced (CLA) exercise to open-loop therapy (OL). Adults with T1D, insulin pump users and HbA1c between 6.0-8.5% were eligible. We investigated glucose control during and 3 hours after exercise. RESULTS Ten subjects (40.8±7.0 years-old; an HbA1c of 7.3±0.8%) participated. The use of the MCL in both closed-loop arms decreased the time <70 mg/dl of sensor glucose (0.0%,[0.0-16.8] and 0.0%,[0.0-19.2] vs. 16.2%,[0.0-26.0], (%,[Percentile 10-90]) CLNA and CLA vs. OL respectively, p=0.047,p=0.063) and the number of hypoglycemic events when compared to OL (CLNA 4 and CLA 3 vs. OL 8; p=0.218,p=0.250). The use of MCL system increased the proportion of time within 70-180 mg/dl (87.8%,[51.1-100] and 91.9%,[58.7-100] vs. 81.1%,[65.4-87.0], (%,[Percentile 10-90]) CLNA and CLA vs. OL respectively, p=0.227, p=0.039). This was achieved with the administration of similar doses of insulin and less amount of carbohydrates. CONCLUSIONS MCL with automatic carbohydrate recommendation performed well and was safe during and after both unannounced and announced exercise maintaining glucose mostly within the target range and reducing the risk of hypoglycemia despite of less amount of carbohydrate intake.